VOYAGEUR PHARMACEUTICALS LTD (VM.CA) Fundamental Analysis & Valuation

TSX-V:VM • CA92918C1014

Current stock price

0.12 CAD
+0.01 (+9.09%)
Last:

This VM.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VM.CA Profitability Analysis

1.1 Basic Checks

  • VM had negative earnings in the past year.
  • In the past year VM has reported a negative cash flow from operations.
  • In the past 5 years VM always reported negative net income.
  • In the past 5 years VM always reported negative operating cash flow.
VM.CA Yearly Net Income VS EBIT VS OCF VS FCFVM.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500K -1M -1.5M -2M

1.2 Ratios

Industry RankSector Rank
ROA -84.97%
ROE -216.61%
ROIC N/A
ROA(3y)-71.36%
ROA(5y)-76.67%
ROE(3y)-198.87%
ROE(5y)-215.24%
ROIC(3y)N/A
ROIC(5y)N/A
VM.CA Yearly ROA, ROE, ROICVM.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • VM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VM.CA Yearly Profit, Operating, Gross MarginsVM.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. VM.CA Health Analysis

2.1 Basic Checks

  • VM has more shares outstanding than it did 1 year ago.
  • VM has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, VM has an improved debt to assets ratio.
VM.CA Yearly Shares OutstandingVM.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VM.CA Yearly Total Debt VS Total AssetsVM.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

2.2 Solvency

  • Based on the Altman-Z score of -2.48, we must say that VM is in the distress zone and has some risk of bankruptcy.
  • A Debt/Equity ratio of 0.03 indicates that VM is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -2.48
ROIC/WACCN/A
WACCN/A
VM.CA Yearly LT Debt VS Equity VS FCFVM.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M -2M

2.3 Liquidity

  • VM has a Current Ratio of 0.58. This is a bad value and indicates that VM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • VM has a Quick Ratio of 0.58. This is a bad value and indicates that VM is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.51
VM.CA Yearly Current Assets VS Current LiabilitesVM.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. VM.CA Growth Analysis

3.1 Past

  • The earnings per share for VM have decreased strongly by -46.67% in the last year.
EPS 1Y (TTM)-46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. VM.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • VM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VM.CA Price Earnings VS Forward Price EarningsVM.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VM.CA Per share dataVM.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0 -0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VM.CA Dividend Analysis

5.1 Amount

  • VM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VM.CA Fundamentals: All Metrics, Ratios and Statistics

VOYAGEUR PHARMACEUTICALS LTD

TSX-V:VM (4/16/2026, 7:00:00 PM)

0.12

+0.01 (+9.09%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.34%
Inst Owner ChangeN/A
Ins Owners9.07%
Ins Owner ChangeN/A
Market Cap21.43M
Revenue(TTM)11.00K
Net Income(TTM)-3.13M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1948.25
P/FCF N/A
P/OCF N/A
P/B 14.85
P/tB 14.85
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -84.97%
ROE -216.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.36%
ROA(5y)-76.67%
ROE(3y)-198.87%
ROE(5y)-215.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16415.4%
Cap/Sales 1940%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.51
Altman-Z -2.48
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)9357.03%
Cap/Depr(5y)11530.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-72.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-90.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-102.93%
OCF growth 3YN/A
OCF growth 5YN/A

VOYAGEUR PHARMACEUTICALS LTD / VM.CA Fundamental Analysis FAQ

What is the fundamental rating for VM stock?

ChartMill assigns a fundamental rating of 0 / 10 to VM.CA.


What is the valuation status of VOYAGEUR PHARMACEUTICALS LTD (VM.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to VOYAGEUR PHARMACEUTICALS LTD (VM.CA). This can be considered as Overvalued.


How profitable is VOYAGEUR PHARMACEUTICALS LTD (VM.CA) stock?

VOYAGEUR PHARMACEUTICALS LTD (VM.CA) has a profitability rating of 0 / 10.